WO2007074864A1 - Anticorps capable de reconnaitre la dimethylarginine asymetrique, procede pour la production de l'anticorps, et procede pour la detection de proteine ayant un acide amine modifie de maniere post-traductionnelle - Google Patents

Anticorps capable de reconnaitre la dimethylarginine asymetrique, procede pour la production de l'anticorps, et procede pour la detection de proteine ayant un acide amine modifie de maniere post-traductionnelle Download PDF

Info

Publication number
WO2007074864A1
WO2007074864A1 PCT/JP2006/326045 JP2006326045W WO2007074864A1 WO 2007074864 A1 WO2007074864 A1 WO 2007074864A1 JP 2006326045 W JP2006326045 W JP 2006326045W WO 2007074864 A1 WO2007074864 A1 WO 2007074864A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
antibody
amino acid
adma
post
Prior art date
Application number
PCT/JP2006/326045
Other languages
English (en)
Japanese (ja)
Inventor
Yasuhiko Komatsu
Hisako Iwabata
Masayuki Ota
Original Assignee
Advanced Life Science Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Life Science Institute, Inc. filed Critical Advanced Life Science Institute, Inc.
Publication of WO2007074864A1 publication Critical patent/WO2007074864A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins

Definitions

  • the present invention relates to a novel antibody or antibody fragment that specifically reacts with asymmetric dimethylarginine, a hybridoma that produces the antibody, a method for producing the antibody, and asymmetric dimethylarginine using the antibody.
  • the present invention relates to a method for detecting a contained protein.
  • Methyl arginine includes symmetric dimethyl arginine (hereinafter sometimes referred to as SDMA), asymmetric dimethyl arginine (hereinafter sometimes referred to as ADMA), and an intermediate from arginine to SDMA or ADMA.
  • SDMA symmetric dimethyl arginine
  • ADMA asymmetric dimethyl arginine
  • MMA monomethylarginine
  • ADMA in blood is thought to affect NO metabolism in vascular tissues and vascular endothelial function, and is considered to be related to arteriosclerotic lesions.
  • Non-Patent Document 1 “Molecular & Cellular Proteomics” (USA), 2003, No. 2, No. 12, p. 1319-1330 Disclosure of the Invention
  • the present inventors thought that asymmetric dimethylarginine exists in addition to the region of the RG rich cluster of the protein.
  • Conventional antibodies were thought to detect proteins with ADMA present in RG-rich clusters. It was difficult to analyze proteins with ADMA existing in other regions.
  • the present inventors have immunized animals with a complex in which a peptide having a structure different from that of a conventional immunogen is bound to a carrier protein. It has been found that an antibody exhibiting reactivity different from that of a known anti-ADMA antibody can be prepared.
  • the antibody of the present invention can detect ADMA present in proteins with a small positive charge.
  • the present inventors have found a method for detecting a basic protein containing ADMA, which has not been identified in the past, by combining the antibody of the present invention with a chemical modification of a protein, in particular, acetylene cocoon.
  • the present invention is based on these findings.
  • the above-mentioned problem is obtained by chemically modifying a protein side chain on a protein containing asymmetric dimethylarginine and reacting specifically with asymmetric dimethylarginine.
  • This can be solved by an antibody that reacts specifically with the metric dimethylarginine-containing protein.
  • the antibody of the present invention it specifically binds to asymmetric dimethylarginine and has the formula (4):
  • ADMA is asymmetric dimethylarginine
  • BSA is ushi serum albumin
  • the antibody of the present invention is a mouse monoclonal antibody, in particular, an antibody secreted and produced by a hybridoma having the accession number FERM BP-10458.
  • the present invention also relates to an antibody fragment, which is a fragment of the antibody, comprising an antigen-binding site that specifically reacts with asymmetric dimethylarginine.
  • the present invention also relates to a hybridoma that produces the above-mentioned antibody, and in particular, a high number having the accession number FERM BP-10458. About Pridoma.
  • the present invention also relates to a method for producing an anti-asymmetric dimethylarginine antibody, characterized in that a peptide represented by the sequence of [5 is a peptide fragment consisting of 5] is bound to a carrier protein to immunize an animal.
  • the peptide is represented by the general formula (9), wherein X is Gly and Z is ⁇ -aminocaproic acid.
  • the animal is an autoimmune disease mouse, particularly an MRL lprZlpr mouse.
  • the present invention includes (1) a step of chemically modifying a protein side chain on a test sample that may contain a post-translationally modified amino acid-containing protein, and (2) a protein side chain.
  • the present invention also relates to a method for detecting the post-translationally modified amino acid-containing protein, comprising a step of detecting a binding (complex) between the chemically modified post-translationally modified amino acid-containing protein and the probe.
  • a preferred embodiment of the method for detecting a post-translationally modified amino acid-containing protein of the present invention is a protein containing a post-translationally modified amino acid-containing protein strength asymmetric dimethylarginine.
  • the chemical modification of the protein side chain is acylation or alkylation.
  • the antibody or antibody fragment specifically reacts with the probe power ADMA for the modified amino acid.
  • the method further comprises a step of fractionating the protein by isoelectric point, molecular weight, or a combination of isoelectric point and molecular weight.
  • the present invention provides (1) a test that may contain a post-translationally modified amino acid-containing protein.
  • a process for changing the charge of the protein on the sample (2) a process for separating the test sample subjected to the charge change by isoelectric point of the protein; and (3) after the separation.
  • the present invention also relates to a method for detecting a post-translationally modified amino acid-containing protein, comprising a step of detecting.
  • fractionation based on the molecular weight of a protein is performed before or after the fractionation step.
  • the probe is an antibody against methyllysine.
  • the antibody of the present invention is useful for searching for and identifying a protein containing asymmetric dimethylarginine.
  • the post-translationally modified amino acid-containing protein detection method combining the antibody and protein chemical modification of the present invention has made it possible to identify a powerful protein containing ADMA that could not be identified conventionally.
  • the antibody and detection method of the present invention it becomes possible to identify an ADMA-containing protein as a target molecule associated with a disease.
  • the antibody of the present invention can be used for therapy by controlling the function of a target molecule associated with the identified disease and for diagnosis by detecting the target molecule.
  • FIG. 1 Antibody titer of immunized mice Shows the antibody titer in blood by the ELISA method of BalbZc and MRL-lprZlpr mice 3 days after the final immunization with RME-GaR £ AC-KLH complex.
  • FIG. 2 Monoclonal antibody reactivity (ELISA by antigen) Established mouse monoclonal antibody DMA2—2G11, ADMA2—2H5, ADMA2—2H7, ADMA2—4E6, A DMA2—5E10, or ADMA2—3C10 (sub) Clones ADMA2—3C10A and A DMA2-3C10B) ADMA-containing peptides RME-LaRC-BSA (A), RME-GaRKC—BSA (B), RME—GaR ⁇ AC—BSA (C), and ADMA-free peptides The reactivity with a troll peptide is shown.
  • FIG. 4 Inhibition of monoclonal antibody reaction by amino acids (ELISA) Inhibition of mouse monoclonal antibodies ADMA2-5E10, ADMA2-3C10, and ADMA2-2H5 by ADMA, MMA, or arginine (Arg). Show.
  • FIG. 5 Effect of sulfo NHS acetate (ELISA)
  • RME-GaRKC-BSA 10 ⁇ g / mL
  • LRGRGRKC—BSA sulfo NHS acetate
  • the mouse monoclonal antibodies ADMA2-5E10, ADMA2-3C10 3 shows changes in reactivity of ADMA2-2H5, polyclonal antibody ASYM24, and monoclonal antibody Clone 7E6.
  • FIG. 6 Effect of sulfo NHS acetate (Western) The reactivity of mouse monoclonal antibody ADM A2-2H5 and polyclonal antibody ASYM24 to the protein of MOLT-4F cells treated or not treated with sulfo NHS acetate is shown.
  • ACK2F12 is a monoclonal antibody against acetyl lysine, indicating that the protein lysine is acetylated.
  • FIG. 7 Western blotting of mouse organs Western blotting using mouse monoclonal antibody ADMA2-2H5 for the extracted tissue protein.
  • FIG. 8 shows the results of Western blotting using mouse monoclonal antibody ADMA2-2H5 after 2D electrophoresis of 2D- Western HepG2 cell protein of HepG2 lysate.
  • FIG. 9 Detection of ADMA-containing protein by sulfo NHS acetate treatment Western blotting using mouse monoclonal antibody ADMA2-2H5 after two-dimensional electrophoresis of protein of HepG2 cells with sulfo NHS acetate treatment or untreated. Show fruit.
  • FIG. 10 Detection of methyllysine-containing protein by treatment with sulfo NHS acetate Shows the results of Western blotting using mouse monoclonal antibody MEK3D7 after 2D electrophoresis of proteins in Hep G2 cells treated with sulfo NHS acetate or untreated .
  • ADMA asymmetric dimethylarginine
  • SDMA symmetric dimethylarginine
  • the antibodies of the present invention include monomethylarginine and arginine. It is an antibody that reacts specifically with ADMA and does not react with ginin. That is, specifically reacting with ADMA means reacting with ADMA but not with SDMA, monomethylarginine, and arginine.
  • the antibody of the present invention specifically reacts with a complex of the following three types of peptides containing ADMA and BSA.
  • RME—GaRKC—BSA RME—GaRKC—BSA
  • the antibody of the present invention does not react with the following peptide-BSA complex containing SDMA and methylated! /, NA! /, Arginine.
  • RME LsRC—BSA
  • the antibody of the present invention is a complex of RSA-GaRKC-BSA lysine acetylated peptide and BSA.
  • RME—GaRacKC—BSA RME—GaRacKC—BSA
  • the antibody of the present invention does not react with LRGRGRKC- BSA lysine acetylated complex, and therefore reacts with ADMA rather than reacting with peptide or BSA acetylated lysine. . Furthermore, the antibody of the present invention becomes highly reactive to proteins by acetylating lysine contained in proteins in cells. Therefore, by acetylating the protein, it becomes possible to detect a protein containing ADMA, which has been impossible to detect conventionally.
  • Clone 7E6 which is a commercially available monoclonal antibody against ADMA, does not react with RME-GaRKC-BSA or RME-GaRacKC BSA.
  • the ASYM24 antibody which is a polyclonal antibody obtained using an ADMA-G rich peptide as an immunogen, is more reactive to RME-GaRKC-BSA than RME-GaRacKC-BSA, in contrast to the antibody of the present invention. To do.
  • the ASYM24 antibody becomes less reactive to the protein by acetylating lysine contained in the protein in the cell.
  • the antibody of the present invention is characterized in that the binding force of the antibody to RME-GaRacK C BSA is stronger than the binding force to RME-GaRKC-BSA.
  • the strong binding force means that the affinity constant is high, the dissociation constant is low, or the binding amount of the antibody is increased.
  • the binding force of the antibody of the present invention to RME—GaRKC BS A or RME—GaRacKC—BSA can be measured by solid-phase enzyme immunoassay (ELISA), Western blotting, radioimmunoassay, etc. is there.
  • RME—Ga RKC-BSA (10 g / mL) is immobilized on an ELISA plate.
  • Antibody to be measured Dilute to 1000 ngZmL, 333 ng / mL, ll lng / mL, 37 ng / mL, 12.3 ng / mL, 4.
  • the binding force of the antibody to RME-GaRacKC-BSA is stronger in any of the above-mentioned antibody concentrations by ImM treatment or 10 mM treatment than OmM treatment (untreated) of sulfo NHS acetate.
  • Absorbance power at 492 nm Specifically, the strong binding force of an antibody indicates that the absorbance (A) of sulfo NHS acetate in ImM treatment or 10 mM treatment is the absorbance (B) of sulfo NHS acetate in OmM treatment.
  • (X) Force means greater than 1, preferably 1.01 or more, more preferably 1.1 or more, and even more preferably 1.5 or more.
  • An increase in binding force can also be expressed by an increase in association constant (Association constant, Ka) or a decrease in dissociation constant (Dissociation constant, Kd).
  • association constant, Ka association constant
  • dissociation constant, Kd dissociation constant
  • the reaction in which an antigen and an antibody are combined to form an antigen-antibody conjugate is a reversible reaction. When the reaction reaches equilibrium, the concentrations of unbound antigen, unbound antibody, and antigen-antibody conjugate are respectively Ag], [Ab], [Ag'Ab]
  • Kd [Ag] [Ab] Z [Ag'Ab], which can be obtained by analysis such as Scatchard plot using radiolabeled antigen. An approximate value can also be obtained by ELISA. For example,
  • [Ag'Ab] Ab-[Ag] / (Kd + [Ag]) It becomes.
  • Kd can be estimated by assuming that [Ag] is hardly affected by the binding of Ag in the liquid phase and is proportional to the signal strength [Ag 'Ad] after washing in the ELISA method. And a decrease in the value of Kd represents an increase in binding force.
  • This estimation method is particularly effective when the concentration of the adsorbed antibody is sufficiently smaller than the Kd value.
  • strong antibody binding means that Ka in sulfo NHS acetate ImM treatment or 10 mM treatment is greater than the value of 1 when divided by Ka in sulfo NHS acetate OmM treatment, Preferably it is 1.01 or more, More preferably, it is 1.1 or more, More preferably, it is 1.5 or more.
  • strong antibody binding means that the Kd in OmM treatment of sulfo NHS acetate divided by Kd in ImM treatment or 10 mM treatment of sulfo NHS acetate is greater than 1. Preferably it is 1.01 or more, More preferably, it is 1.1 or more, More preferably, it is 1.5 or more.
  • the antibody of the present invention includes a polyclonal antibody and a monoclonal antibody, more preferably a monoclonal antibody.
  • the antibody fragment of the present invention is a fragment of the antibody of the present invention, and is an antibody fragment that has the same reaction specificity as the original antibody. That is, the antibody fragment of the present invention specifically reacts with ADMA and does not react with SDM A, monomethylarginine, or unmethylated arginine.
  • RME-GaRacKC-BSA which is a peptide in which lysine continuous with ADMA is acetylated, exhibits a stronger response than RME-GaRKC-BSA, and acetylates lysine contained in proteins in cells. Increases the reactivity to proteins.
  • Examples of the antibody fragment of the present invention include Fab, Fab ⁇ F (ab '), or Fv
  • fragments can be obtained, for example, by digesting the monoclonal antibody of the present invention with a proteolytic enzyme according to a conventional method, and subsequently following a conventional method for protein separation and purification.
  • the antibody of the present invention has the general formula (9): X-ADMA-Z-Cys (9)
  • X is a peptide fragment consisting of the same or different amino acid residues 1 to 5 other than Cys
  • ADMA is asymmetric dimethylarginine
  • Z is the same or different amino acid residues 1 to 5 other than Cys. It is a peptide fragment consisting of 5]
  • the peptide represented by the sequence can be prepared by binding to a carrier protein and immunizing an animal.
  • X is any amino acid other than cysteine.
  • X is not particularly limited as long as it is an amino acid other than Cys, but amino acids that do not affect ADMA on the C-terminal side are preferred.
  • amino acids having nonpolar side chains and uncharged polar side chains Is preferred.
  • Specific amino acids include glycine, alanine, parin, serine and the like, with glycine being particularly preferred.
  • the continuous length of the amino acid of X is not particularly limited, but is preferably an integer of 1 to 5, and more preferably 1.
  • Z is also any amino acid other than cysteine.
  • Z is not particularly limited as long as it is an amino acid other than Cys, but preferably an amino acid that does not affect ADMA on the N-terminal side, for example, an amino acid whose side chain has a nonpolar side chain and an uncharged polar side chain.
  • Specific examples of amino acids include glycine, alanine, Norin, serine, and ⁇ -aminocaproic acid (6-aminocaproic acid), and ⁇ -aminocaproic acid (6-aminocaproic acid) is particularly preferable.
  • the continuous length of the wrinkles is not particularly limited, but is preferably an integer of 1 to 5, more preferably 1.
  • the peptide represented by the general formula (9) is bound to a carrier protein using the thiol group (SH group) of Cys on the C-terminal side. For this reason, when Cys is contained in X or Z, Cys other than the C-terminal side may bind to the carrier protein and ADMA may be hidden, which is not preferable in terms of the structure of the immunogen.
  • the peptide of the general formula (9) can be prepared by chemical synthesis, for example, Fmoc solid phase synthesis method or Boc solid phase synthesis method.
  • the synthesized peptide can be purified by a known method such as HPL C.
  • the peptide is bound to a carrier protein using the SH group of Cys of the peptide of the general formula (9).
  • the “carrier protein” is not particularly limited as long as it is a protein capable of binding to the peptide to form a complex and exhibiting immunogenicity. More than 10,000, preferably 40,000 to 1 million proteins are preferred. Specific examples include sushi serum albumin, immunoglobulin, ovalbumin, mosquito hemocyanin (KLH), and the like.
  • the peptide and carrier can be bound using the SH group of cysteine and the functional group of the carrier protein.
  • the functional group of the carrier protein is not limited as long as it is a functional group that binds to the SH group, and includes a thiol group or an amino group.
  • the binding method can be carried out according to a conventionally known method. For example, maleimide, carbodiimide, glutaraldehyde, sulfo GMBS, or GMBS can be used as a cross-linking agent between a peptide and a carrier protein. it can.
  • the antibodies of the present invention include animal polyclonal antibodies and human mouse monoclonal antibodies.
  • Methods for immunizing animals to obtain antibodies and methods for obtaining hyperprideomas producing monoclonal antibodies It can be carried out by a known method except that a complex of the peptide of the general formula (9) and a carrier protein is used as an immunogen.
  • a complex of the peptide of the general formula (9) and a carrier protein is used as an immunogen.
  • it can be performed according to the method described in the Second Biochemistry Experiment Course (Japan Biochemical Society) or the Immunobiological Research Method (Japan Biochemical Society).
  • the antibody of the present invention can be obtained by immunizing an animal using the complex of the peptide of the general formula (9) and a carrier protein as an immunogen.
  • the animal used for immunization is not particularly limited, and hidge, goat, rabbit, mouse, rat, guinea pig, bird, horse, horse and the like can be used.
  • the animal used for immunization is preferably an animal with an autoimmune disease that easily produces autoantibodies.
  • an MRL-lprZlpr mouse which is an autoimmune disease mouse.
  • the immunization method is not particularly limited as long as a known method is used.
  • the complex is emulsified and mixed with an equal amount of Freund's complete adjuvant or Titer-Max gold (Titer Max), and a rabbit is used. Administered subcutaneously or intraperitoneally in mice. Thereafter, immunize several times with the same procedure at 1-2 week intervals.
  • the antibody of the present invention can be prepared by collecting the blood of the immunized animal to obtain serum or plasma.
  • the hyperidoma of the present invention that produces the monoclonal antibody of the present invention can be obtained from an animal that has undergone the above-described immunization.
  • the peptide dissolved in phosphate buffered saline (PBS) or the like is inoculated from the tail vein.
  • PBS phosphate buffered saline
  • the spleen containing lymphocytes that produce mouse antibody is aseptically removed.
  • This lymphocyte can be established as a hybridoma that produces a monoclonal antibody by cell fusion with myeloma cells in the presence of polyethylene glycol, for example.
  • lymphocytes and myeloma cells are fused in the presence of polyethylene glycol.
  • myeloma cell various known cells can be used, and examples thereof include cells such as p3-NS-l / l-Ag4.1 or SP2Z0-Agl4.
  • Fused cells are selected by killing non-fused cells using a selective medium such as HAT medium.
  • screening is performed for the presence or absence of antibody production in the culture supernatant of the growing hyperidoma. Screening can be performed by measuring the production of specific antibodies against asymmetric dimethylarginine by solid phase enzyme immunoassay (ELISA).
  • ELISA solid phase enzyme immunoassay
  • FERM BP-10458 producing the representative monoclonal antibody of the present invention can be selected. As of November 30, 2005, it was deposited internationally at the National Institute of Advanced Industrial Science and Technology patent biological deposit center (address: 1st, 1st, 1st, 1st, 6th, Tsukuba, Higashi 305-8566, Japan). It was.
  • the hyperidoma of the present invention can be subcultured in any known medium, for example, RPMI1640.
  • the monoclonal antibody of the present invention can be prepared by culturing this hyperidoma, for example, by adding 10% fetal bovine serum to RPMI1640 medium and culturing at 37 ° C in the presence of 5% CO. Antibody produced in the culture supernatant
  • antibodies can be produced in ascites by inoculating Hypridoma into the abdominal cavity of mice and collecting ascites.
  • the antibody of the present invention can be purified by a known method. For example, a purification method using Protein G, a method using a affinity column to which ADMA is bound, or a method using ion exchange column chromatography. It can be purified by methods.
  • the antibody of the present invention reacts more strongly with RME-GaRacKC-BSA in which lysine of RME-GaRKC-BSA is acetylated than with RME-GaRKC-BSA. Furthermore, by reacting cell protein lysine with acetylene, reactivity to many proteins is enhanced. By utilizing this property of the antibody of the present invention, it becomes possible to detect a protein containing ADMA, which could not be detected until now. In other words, since the binding between the antibody of the present invention and ADMA in the protein is strengthened by acetylating the protein, it can be bound to a protein having strong ADMA that could not be identified conventionally.
  • Clone 7E6 a conventionally known antibody, cannot bind to acetylated protein.
  • ASYM24 antibody recognizes RG-rich cluster ADMA and becomes less reactive to acetylated protein, it cannot be effectively used in the method for detecting a post-translationally modified amino acid-containing protein of the present invention.
  • lysine of RME-GaRKC-BSA is a basic amino acid.
  • the acetyl group replaces the hydrogen atom of the side chain of the lysine with the acetyl group. Therefore, it is considered that the positive charge of lysine disappears.
  • the antibody of the present invention is capable of recognizing ADMA.
  • ADMA When a basic amino acid is present in the vicinity of ADMA, binding to ADMA is considered to be inhibited under the influence of positive charge. However, when lysine is acetylated, the positive charge around ADMA is weakened, and the binding of the antibody of the present invention to ADMA is thought to increase. In the case of intracellular proteins, as in the case of the aforementioned peptides, the positive charge around ADMA is neutralized by the acetylation of the lysine amino group present around ADMA recognized by the antibody of the present invention. It may be considered that the antibodies of the present invention can be combined and bind!
  • ASY is a known antibody obtained using an ADMA-G rich peptide as an immunogen.
  • M24 has the ability to weaken the reactivity to the protein by acetylating the lysine of the protein of the cell.
  • ADMA-G-rich peptide is an antibody with a strong positive charge. It is thought that it binds to peptides and proteins with strong positive charges in the vicinity.
  • a method for detecting two post-translationally modified amino acid-containing proteins will be described.
  • (1) a protein side chain is chemically modified on a test sample that may contain a post-translationally modified amino acid-containing protein.
  • the second method for detecting a post-translationally modified amino acid-containing protein of the present invention comprises (1) a treatment for changing a protein charge on a test sample that may contain a post-translationally modified amino acid-containing protein. Steps to be performed, (2) Steps for performing separation by isoelectric point of proteins for test samples subjected to charge change treatment, (3) Specific reaction to post-sorting test samples and post-translationally modified amino acids And (4) detecting the binding between the separated protein and the probe formed by the contacting step. [Hereinafter referred to as charge change detection method] In the chemical modification detection method and the charge change detection method of the present invention, the above steps are usually performed in this order.
  • test sample used in the chemical modification detection method and the charge change detection method of the present invention is not particularly limited as long as it may contain a post-translationally modified amino acid-containing protein.
  • the post-translationally modified amino acid-containing protein detected by the chemical modification detection method and the charge change detection method of the present invention is not limited as long as it contains a post-translationally modified amino acid.
  • the post-translationally modified amino acid recognized by the probe in the chemical modification detection method and the charge change detection method of the present invention is not limited as long as it is an amino acid modified after translation in vivo.
  • examples include amino acids that are phosphorylated, ubiquitinated, acetylated, methylated, farnesylated, sulfated, carboxylated, glycosylated, or lipid modified, and specifically, asymmetric dimethylarginine.
  • the chemical modification detection method is preferably asymmetric dimethylargin, and the charge change detection method is methyllysine.
  • the chemical modification carried out by the chemical modification detection method of the present invention is not particularly limited, but alkylation, acylation, acetylation, amido, glycosylation, succination, phosphorylation, sulfation, Forces such as reboylation, force rubymilation, or methyl cocoon Acidic proteins that favor chemical modification that changes the isoelectric point of the protein when combined with the separation of proteins by isoelectric point
  • a chemical modification that neutralizes the negative charge is preferable
  • a chemical modification that neutralizes the positive charge is preferable.
  • acylic acid in the case of a basic protein, it is preferably acylic acid, and it is not limited as long as it replaces an amine group or a hydroxyl group with an isyl group, and examples thereof include acetylation and benzoylation. Acetyl cocoon is preferable.
  • the acetylene is not limited as long as the amino acid in the protein is acetylylated. As the amino acid to be acetylated, the positive charge disappears when acetylene is used.
  • the acetylating reagent is not particularly limited, and examples thereof include acetic anhydride, N-acetylsuccinimide, N-hydroxysuccinimide acetate (NHS-acetate), N-acetylenomidazole, and sulfo-NHS acetate.
  • the chemical modification in the relationship with the probe that binds to the post-translationally modified amino acid, the chemical modification that inhibits the binding to the probe by chemical modification is not preferable, and the chemical bond is stronger, so that the probe binding becomes stronger. Chemical modification is preferred.
  • chemical modification that neutralizes negative charges is preferable.
  • chemical modification that neutralizes positive charge is preferred.
  • lysine acetylene is preferred.
  • the probe used in the chemical modification detection method of the present invention may be a probe capable of recognizing a post-translationally modified amino acid present in a protein subjected to chemical modification of a protein side chain.
  • modified amino acids such as phosphorylated, ubiquitinated, acetylated, methylated, farnesylated, sulfated, carboxylated, glycosylated, or lipid modified amino acids
  • An antibody is mentioned, More preferably, it is an antibody with respect to ADM A.
  • the post-translationally modified amino acid-containing protein is chemically modified.
  • the post-translationally modified amino acid-containing protein is chemically modified to prevent the antibody from reacting with the protein.
  • the antibody used in the detection method of the present invention can bind to a chemically modified protein, and preferably, the reactivity with a post-translationally modified amino acid is reduced by chemically modifying the protein. More preferably, the antibody is more reactive.
  • a step of separating the post-translationally modified amino acid-containing protein can be further performed.
  • the method for fractionation is not particularly limited as long as it is a method for fractionating proteins.
  • force using a known method can be used, for example, electrophoresis using talylamide gel or capillary.
  • the fractionation step may be performed before or after any step of the detection method, but is preferably before the step (2) of contacting with a probe that recognizes a post-translationally modified amino acid. This is because the isoelectric point of the molecular weight may change due to the binding between the probe and the protein, which may make the analysis difficult.
  • Methods for separating proteins include a method using molecular weight, a method using isoelectric point, and a method using other principles. These methods can be performed alone or in combination. To separate many proteins, a combination of multiple separation principles is preferred. For example, isoelectric point Two-dimensional electrophoresis combined with fractionation by molecular weight.
  • the “basic protein” means a protein having an isoelectric point on the basic side, for example, a protein having 7.0 or more, preferably 8.0 or more, more preferably 9.0 or more. is there.
  • a method for detecting all proteins in a specimen The force that can be used as it is.
  • Preferably, only acidic protein or basic protein is separated and used in the detection method.
  • known protein separation methods can be used. For example, an ion exchange chromatography column can be used.
  • the charge change process carried out by the charge change detection method of the present invention is not particularly limited as long as it is a process that changes the charge of the protein !, but changes the charge using a covalent bond or a non-covalent bond. Can be combined. In the case of non-covalent bonds, ionic bonds and hydrophobic bonds can be used. When a covalent bond is used, the charge of the protein can be changed, for example, by chemically modifying the amino acid side chain of the protein.
  • the chemical modification is not particularly limited, but alkylation, acylation, acetylation, amidation, glycosylation, succination, phosphorylation, sulfation and reboylation, force ruamylation, methylation, phosphorylation, or sulfuric acid
  • acidic proteins chemical modifications that neutralize negative charges are preferred
  • basic proteins chemical modifications that neutralize positive charges are preferred.
  • a basic protein it is preferably an acyl group, and any amine group or hydroxyl group may be substituted with an isyl group, and examples thereof include acetylation and benzoylation, and more preferably. Acetylation.
  • Acetylation is not limited as long as an amino acid in a protein is acetylated.
  • amino acid to be acetylated lysine can be cited as the acetylated amino acid, thereby eliminating the positive charge.
  • the reagent for acetylation is not particularly limited, but acetic anhydride, N-acetylsuccinimide, N-hydroxysuccinimide acetate (NHS-acetate), N-acetylimidazole, or sulfo NHS acetate (sulfo-NHS acetate) Are listed.
  • the charge mutation treatment is not preferable in terms of the relationship with the probe that binds to the post-translationally modified amino acid, and charge mutation treatment that inhibits binding to the probe by charge mutation treatment is not preferable. Is preferable. For example, in the case of a probe that does not easily bind to an acidic protein, charge mutation treatment that neutralizes negative charges is preferable. In the case of a probe that does not easily bind to a basic protein, charge mutation treatment that neutralizes positive charge is preferred. For example, lysine acetylation by chemical modification is preferred.
  • the probe used in the charge change detection method of the present invention is not particularly limited as long as it is a probe capable of recognizing a post-translationally modified amino acid present in a protein subjected to charge change treatment of a protein side chain.
  • Phosphorylated, ubiquitinated, acetylated, methylated, farnesylated, sulfated, carboxylated, glycosylated, and lipid modified amino acids which are antibodies that bind to glycine, and preferably antibodies against methyllysine .
  • the post-translationally modified amino acid-containing protein is subjected to charge change treatment, and therefore an antibody that does not react with the protein by the charge change treatment of the post-translationally modified amino acid-containing protein cannot be used. Therefore, the antibody used in the detection method of the present invention can bind to a protein subjected to charge change treatment.
  • the reactivity of the protein to a post-translationally modified amino acid is reduced by subjecting the protein to charge change treatment. More preferably, the antibody is more reactive.
  • Fractionation by isoelectric point to be performed in step (2) of the charge change detection method of the present invention is not particularly limited as long as it is a method of separating proteins by isoelectric point.
  • An example is point electrophoresis.
  • two-dimensional electrophoresis that combines separation by isoelectric point and molecular weight is preferred. Can be mentioned.
  • the probe bound to the post-translationally modified amino acid can be detected by a known method.
  • the probe can be detected by labeling the probe with a labeling substance.
  • An enzyme eg, peroxidase or alkaline phosphatase
  • a fluorescent dye eg, fluorescein isothiocyanate (FITC)
  • FITC fluorescein isothiocyanate
  • luminescent substance e.g, fluorescein isothiocyanate (FITC)
  • FITC fluorescein isothiocyanate
  • radioactive substance e.g, a radioactive substance.
  • these labeling substances can be detected by a known color development method, luminescence method, fluorescence method or the like.
  • Gly—ADMA—Lys—Cys (shown as SEQ ID NO: 3; hereinafter referred to as RME—GaRKC)
  • RME—LsRC Leu—SDMA—Cys
  • Gly is glycine
  • ADMA is asymmetric dimethyl arginine
  • Acp is epsilon aminocaproic acid
  • Cys is cysteine
  • Leu is leucine
  • SDMA is symmetric dimethylarginine
  • the RME-GaR ⁇ AC peptide was bound to KLH, which is a carrier protein, through C-terminal Cys. That is, KLH (Nacalai Testa Co.) or BSA (Sigma) lOmg was dissolved in PBS lmL containing 5 mM EDTA, and then the crosslinking agent GMBS (N- ⁇ -maleimidobutyryloxysulfosuccinimide ester ( ⁇ ( ⁇ Maleim laobutyryloxy) sulfosuccinimide ester: Concentration 20mg / mL, Dojinki) ⁇ 3.5 ⁇ L was added and allowed to react at 30 ° C for 30 minutes with stirring, and then a PD-10 column (Farmasia Biotech) was added.
  • GMBS N- ⁇ -maleimidobutyryloxysulfosuccinimide ester
  • RME-LaRC, RME—GaRKC® RME—: LPERC and LRGRG RKC are used as peptides, and the complex of each peptide and BS A is prepared by the same procedure as that for the RME GaR ⁇ AC and BSA. Prepared. Obtained RME—LaRC, RME-GaRKC, RM The complex of E—LsRC and LRGRGRKC peptide and BSA is referred to as RME—La RC—BSA RME—GaRKC—BSA RME—: LsRC—BSA ⁇ and LRGRGRKC BSA, respectively.
  • the RME—GaR ⁇ AC KLH complex antigen solution (2 mg / mL) obtained in Example 1 was mixed with an equal amount of Titer—Max Gold (Titer Max USA) until emulsified, and the mixed solution 0. ImL was added.
  • Immunization was carried out by intraperitoneal administration of three 6-week-old female BalbZc mice or 3 6-week-old female MRL-lprZlpr mice (MRLZMpJUmmCrjlprZlpr mice). (First immunization). Twice every 2 weeks, 0. ImL of the mixed solution prepared in the same manner as in the previous period was administered intraperitoneally (second and third immunizations).
  • mice with increased antibody titers were diluted with an equal volume of PBS, and 0.1 mL of the diluted solution was administered to the abdominal cavity of the mice.
  • RME-GaR ⁇ Yoji-10 ⁇ 1 complex antigen solution (2111 8 7111 was diluted with an equal volume of PBS, and 0.0 ImL of the diluted solution was administered intravenously to mice.
  • the mouse-powered spleen was aseptically removed and used in the following cell fusion step (C).
  • each of the RME-GaRKC-BS A complex (10 ⁇ g / mL) prepared in Example 1 was dispensed into a 96-well ELISA plate (Nunc) and left at 4 ° C. overnight. Next, each well of the plate was blocked with phosphate buffered saline (PBS) containing 1% BSA and 0.05% Tween 20 (hereinafter referred to as 1% BSA-PBST) for 30 minutes. After removing this supernatant, the serum obtained in the above step (A) was diluted from 30 times to 7290 times with PBST, and 50 / z L was added.
  • PBS phosphate buffered saline
  • Tween 20 hereinafter referred to as 1% BSA-PBST
  • the antibody titer against RME-GaRK C-BSA was increased in both BalbZc mice and MRL-lprZlpr mice.
  • the antibody titer of MRLlpZlpr mice was particularly high, and one mouse (MRL-1) showed a very high antibody titer.
  • the spleen of the aseptically extracted MRL-1 mouse was placed in a petri dish containing 8 mL of sterile PBS. After spleen cells were drained, the spleen cell suspension was passed through a nylon mesh, collected in a 15 mL centrifuge tube, and centrifuged at 380 X g for 3 minutes. After performing this operation twice, the suspension was suspended in 8 mL of RPMI medium and centrifuged at 380 X g for 3 minutes. This operation was performed twice. The cell pellet thus obtained was resuspended in 8 mL of RPMI 1640 medium, and the number of splenocytes was measured.
  • mouse myeloma cells (myeloma cells) cultured in advance in 50 mL tubes were spalled into the spleen cells (approximately 1 ⁇ 10 7 cells) S P2Z0—Agl4 5 ⁇ 10 7 ), mixed well in RPMI1640 medium, and centrifuged (380 ⁇ g, 5 minutes) o Aspirate the supernatant, thaw the pellet well, and incubate at 37 ° C 1 mL of the 40% polyethylene glycol (PEG) 4000 solution was dropped, and the centrifuge tube was gently rotated by hand for 1 minute to mix the PEG solution and the cell pellet.
  • PEG polyethylene glycol
  • HAT medium (RPMI1 640 medium ⁇ this aminopterin 4 X 10 _7 M, thymidine 1. 6 X 10 _5 M, and hypoxanthine 1 X 10 _4 those that have been ⁇ Ka ⁇ such that M) was suspended in 50 mL.
  • the high-pridoma was screened in the same manner as the antibody titer measurement by the ELISA method in the above step (ii), except that 50 ⁇ L of the high-pridoma culture supernatant was used instead of the serum-powered sample. Each hyperidoma in the well where antibody production was observed was cloned by the limiting dilution method. Ten days later, a hybridoma clone producing the monoclonal antibody of the present invention was screened by the same ELISA method. as a result
  • ADMA2-2G11, ADMA2-2H5, ADMA2-2H7, ADMA2-4E6, ADM A2-5E10, ADMA2-3C10, six clones of high-pridoma strains were established.
  • Hybridoma cell line ADMA2-2—2H5 (Accession No. FERM BP—10458), dated November 30, 2005, National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (address: 305-8566 Japan) It was deposited internationally at Tsukuba Sakai Higashi 1-chome 1 Ibaraki Pref. 1 Central 6).
  • the established mouse hyperidoma was cultured in a serum-free medium (Hybridoma—SFM, GIBCO) at 37 ° C. in a 5% carbon dioxide atmosphere for 72 to 96 hours.
  • the culture solution was applied to a protein G column (Amersham Biosciences).
  • the antibody was eluted with a buffer solution of pH 3.5 to obtain a purified monoclonal antibody of the present invention. About 20 mg of antibody was obtained from 5 OOmL of the culture solution.
  • the name of each hybridoma is also used as the name of the monoclonal antibody produced by the hyperidoma force.
  • the antibody was labeled with HRP using Pierce's EZ-Link Plus Activated Peroxidase. This method is a method in which HRP into which an aldehyde group is introduced is bound to an amino group in an antibody molecule. Labeling was performed according to the protocol provided by the manufacturer.
  • the HRP-labeled antibody obtained from ADMA2-2H5 is referred to as HRP-ADMA2-2H5.
  • Example 1 50 ⁇ L each of RME—GaR ⁇ AC—BSA, RME—LaRC—BSA, RME—GaRKC—BSA, and control peptide (10 g / mL) prepared in Example 1 on a 96-well ELISA plate Poured and left overnight at 4 ° C. Each well on the plate was then blocked with 1% BSA-PBST for 30 minutes. After removing this supernatant, each antibody obtained in the step (B) of Example 5 and ASYM24 (upstate), which is a polyclonal antibody against ADMA, were diluted with PBST as a control and added in 50 L portions. . After standing at room temperature for 30 minutes, it was washed 3 times with PBST.
  • RME LsRC— BSA
  • LRGRGRKC— BSA ⁇ AcK— BSA (complex of acetylated lysine and BSA) and MeK— BSA (methyllysine and BSA) are antigens that are immobilized on the plate.
  • Clone 7E6 Abeam
  • SYM11 upstate
  • Monoclonal antibody against ADMA and SYM11 is a polyclonal antibody against symmetric dimethylarginine. The results are shown in Figure 3.
  • ADMA2—5E10, ADMA2—3C10, ADMA2—2H5, and ASYM24 do not react to RME—LsR C—BSA, which is a peptide containing SDMA that reacts with peptides containing AD MA, and LRGRGRKC— Neither BSA, AcK-BSA nor MeK-BSA reacted.
  • Clone 7E6 reacted with RME GaR ⁇ AC -BSA and RME-LaRC-BSA, which are peptides containing ADMA, but showed a slightly non-specific reaction even with peptides that did not contain ADMA.
  • SYM11 reacted with RME-LsRC-BSA, a peptide containing SDMA, but showed a strong non-specific reaction with RME-LsR C BSA, a peptide containing ADMA.
  • ADMA2-5E10, ADMA2-3C10, and ADMA2-2H5 were tested for inhibition by ADMA to confirm their specificity.
  • 50 ⁇ L each of RME GaR ⁇ AC BSA (10 ⁇ g / mL) prepared in Example 1 was dispensed into a 96-well ELISA plate and left overnight at 4 ° C. Next, each well of the plate was blocked with 1% BSA-PBST for 30 minutes. Monoclonal antibody and ADMA, monomethylarginine (MMA), or algin (Arg) were mixed and incubated at 25 ° C for 30 minutes.
  • MMA monomethylarginine
  • Arg algin
  • the final concentrations during incubation are 10 ng / mL for AD MA2-2H5, 37 ng / mL for ADMA2-5E10, 2.34 ng / mL for ADMA2-3C10, and each amino acid has a final concentration of 2 ° to 25 mM.
  • diluted with PBST After removing 1% BSA-PBST from the plate, 50 L each of the antibody and amino acid mixture was added. After standing at room temperature for 30 minutes, it was washed 3 times with PBST. Subsequently, 50 ⁇ L (lOOngZmL) of an HRP-labeled anti-mouse IgG antibody was added, left at room temperature for 30 minutes, and washed again with PBST three times.
  • ADMA2-5E10, ADMA2-3C10, ADMA2-2H5, ASYM24 and Clone 7E6 were diluted with P BST and added in 50 L portions. After standing at room temperature for 30 minutes, it was washed 3 times with PBST. Subsequently, 50 L (1 g / mL) of an HRP-labeled anti-mouse IgG antibody (goat) was added, allowed to stand at room temperature for 30 minutes, and then washed again with PBST three times. 100 L of OPD substrate solution was added to each well, reacted at 25 ° C for 10 minutes, and the absorbance at 492 nm of each well was measured. The results are shown in FIG.
  • the ADMA2-5E10, ADMA2-3C10, and ADMA2-2H5 antibodies became more reactive to RME-GaRK C-BSA as the concentration of the treatment with sulfo NHS acetate increased.
  • the serum of MRL 1 mice obtained in step (2) of Example 2 also became more reactive to RME GaRKC BS A as the concentration of treatment with sulfo NHS acetate increased.
  • ASYM24 became less reactive to RME-GaRKC-BSA as the concentration of treatment with sulfo NHS acetate increased.
  • Clone 7E6 did not react with RME—GaRKC—BSA, but it did not increase its reactivity with force sulfo NHS phosphate treatment.
  • MOLT—4F cells (approximately 5 ⁇ 10 6 cells) were added to Lysis buffer (25 mM Tris—HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, ImM CaCl, protease inhibitor potency.
  • the control membrane is 10 mM sulfo NHS No cassette treatment was performed. Blocking was performed by immersing in 10 mM Tris-HC1 buffer (pH 7.5) containing 3% BSA, 3% polybutylpyrrolidone K30 (PVP, Wako) and 0.15M-NaCl for 1 hour at 25 ° C.
  • the monoclonal antibody ADMA2-2H5 antibody (1 ⁇ gZmL) against ADMA obtained in Example 2 was reacted at 25 ° C. for 1 hour.
  • the ADMA2-2H5 antibody which is a monoclonal antibody against ADMA, was enhanced in response to some proteins by treatment with sulfo N HS acetate, and there was almost no protein that weakened the reaction.
  • ASYM24 antibody attenuated the reactivity of MOLT-4F to most proteins ( Figure 6).
  • MOLT-4F force Example 7 except that the extracted protein is used in place of the extracted protein and the membrane to which the protein has been transferred is not treated with sulfo NHS acetate.
  • the mouse organ protein was analyzed with the ADMA2-2H5 monoclonal antibody in the same manner as described above. Tissue protein before The Lysis Buffer was prepared, homogenized and used. The results are shown in FIG. Forces that could detect proteins with ADMA in most tissues In the heart and skeletal muscle, proteins with ADM A were less powerful.
  • Example 9 Analysis of HepG2 cell lysate using ADMA2-2H2 monoclonal antibody (two-dimensional electrophoresis)
  • HepG2 cells were suspended in 2D Lysis buffer [9.8Murea® 0.5% CHAPS® lOmMdithiothreitol (DTT)] and disrupted with ultrasound. The disrupted cell lysate was centrifuged (10,000 X g, 5 minutes), and the supernatant was collected.
  • 2D Lysis buffer 9.8Murea® 0.5% CHAPS® lOmMdithiothreitol (DTT)
  • the strip After stripping, the strip is reduced in 0.375M Tris—HCl (pH8), 6M urea, 2% SDS, 20% glycerol, and 130mMDTT (15 minutes), and further 0.375M Tris—HCl (pH8), Alkylation (15 min) in 6M urea, 2% SDS, 20% glycerol, and 135 mM odoacetamide.
  • 0.375M Tris—HCl pH8
  • 6M urea 6M urea
  • 2% SDS 20% glycerol
  • 135 mM odoacetamide The strip after the reductive alkylation treatment was placed on the SDS polyacrylamide midenore and developed in the second dimension.
  • Proteins in the gel subjected to two-dimensional electrophoresis were electrically transferred to a PVDF membrane.
  • This membrane was soaked in 10 mM Tris-HC1 buffer (pH 7.5) containing 3% BSA, 3% PVP and 0.15M-NaCl for 1 hour at 25 ° C. for blocking.
  • the HRP-ADMA2-2H5 antibody (0.2 / z gZmL) prepared in the step (C) of Example 4 was reacted at 25 ° C for 30 minutes. Wash the membrane 3 times with 10 mM Tris-HC1 buffer (pH 7.5) containing 0.5% Tween-20 and 0.15M NaCl, then use ECL Western Blotting Detection Kit (Amersham Co., Ltd.). Used to carry out a luminescent reaction. This luminescence was detected with LAS-1000 (Fuji Film). The results are shown in FIG.
  • the strip After stripping, the strip is reduced in 0.375M Tris—HCl (pH8), 6M urea, 2% SDS, 20% glycerol, and 130mMDTT (15 minutes), and further 0.375M Tris—HCl (pH8), Alkylation (15 min) in 6M urea, 2% SDS, 20% glycerol, and 135 mM odoacetamide.
  • 0.375M Tris—HCl pH8
  • 6M urea 6M urea
  • 2% SDS 20% glycerol
  • 135 mM odoacetamide The strip after the reductive alkylation treatment was placed on the SDS polyacrylamide midenore and developed in the second dimension.
  • a basic protein was detected in the same manner as in Example 10 except that MEK3 D7 (Japanese Patent Application No. 2003-403313), which is an antibody against methyllysine, was used instead of the HRP-ADMA2-2H5 antibody.
  • MEK3 D7 Japanese Patent Application No. 2003-403313
  • HRP-ADMA2-2H5 antibody an antibody against methyllysine
  • the antibody of the present invention has increased reactivity with respect to acetylated protein, and thus can be used for searching and identifying a protein containing asymmetric dimethylarginine, which could not be detected conventionally.
  • the post-translationally modified amino acid-containing protein detection method combining the antibody of the present invention and the protein acetylene can be used for the search and identification of basic proteins including ADMA that cannot be identified conventionally.
  • the antibody of the present invention can be used for diagnosis that detects a target molecule associated with the identified disease, or for therapeutic treatment by controlling the function of the target molecule.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne : un nouvel anticorps capable de réagir spécifiquement avec la diméthylarginine asymétrique (ADMA) ou un fragment de l'anticorps ; un hybridome capable de produire l'anticorps ; un procédé pour la production de l'anticorps ; et un procédé pour l'analyse d'une protéine basique contenant ADMA utilisant l'anticorps. L'anticorps peut se lier spécifiquement à ADMA et présente une réactivité augmentée à une protéine acylée. Une protéine contenant ADMA n'a pas été identifiée à ce jour, mais il devient désormais possible de détecter la protéine en utilisant la combinaison de l'anticorps et l'acétylation d'une protéine.
PCT/JP2006/326045 2005-12-28 2006-12-27 Anticorps capable de reconnaitre la dimethylarginine asymetrique, procede pour la production de l'anticorps, et procede pour la detection de proteine ayant un acide amine modifie de maniere post-traductionnelle WO2007074864A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-378963 2005-12-28
JP2005378963A JP2007176872A (ja) 2005-12-28 2005-12-28 アシンメトリックジメチルアルギニンを認識する抗体及びその製造方法並びに翻訳後修飾アミノ酸含有タンパク質の検出方法

Publications (1)

Publication Number Publication Date
WO2007074864A1 true WO2007074864A1 (fr) 2007-07-05

Family

ID=38218086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/326045 WO2007074864A1 (fr) 2005-12-28 2006-12-27 Anticorps capable de reconnaitre la dimethylarginine asymetrique, procede pour la production de l'anticorps, et procede pour la detection de proteine ayant un acide amine modifie de maniere post-traductionnelle

Country Status (2)

Country Link
JP (1) JP2007176872A (fr)
WO (1) WO2007074864A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102628868A (zh) * 2011-12-30 2012-08-08 北京九强生物技术股份有限公司 检测非对称二甲基精氨酸含量的胶乳增强免疫比浊法试剂盒
US8481690B2 (en) 2008-08-07 2013-07-09 Idexx Laboratories, Inc. Methods for detecting symmetrical dimethylarginine
CN106290822A (zh) * 2016-07-28 2017-01-04 武汉景川诊断技术股份有限公司 D‑二聚体免疫胶乳微球制备方法及应用
US10775365B2 (en) 2015-02-20 2020-09-15 Idexx Laboratories, Inc. Homogenous immunoassay with compensation for background signal
US11035861B2 (en) 2013-09-05 2021-06-15 Idexx Laboratories, Inc. Methods for detecting renal disease
US11422136B2 (en) 2017-10-19 2022-08-23 Idexx Laboratories, Inc. Detection of symmetrical dimethylarginine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6321921B2 (ja) * 2013-05-10 2018-05-09 学校法人 埼玉医科大学 抗ｔｌｓモノクローナル抗体及びその製造方法、ハイブリドーマ及びその製造方法、並びに抗ｔｌｓモノクローナル抗体含有組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054296A1 (fr) * 2003-12-02 2005-06-16 Advanced Life Science Institute, Inc. Anticorps reconnaissant la methyl-lysine, procede permettant de produire ces anticorps et utilisation de ces anticorps

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054296A1 (fr) * 2003-12-02 2005-06-16 Advanced Life Science Institute, Inc. Anticorps reconnaissant la methyl-lysine, procede permettant de produire ces anticorps et utilisation de ces anticorps

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"DeStreak Rehydration Solution", AMERSHAM BIOSCIENCES, October 2002 (2002-10-01), XP003015039, Retrieved from the Internet <URL:http://www.apczech.cz/pdf/DF_DeStreak.pdf> *
COTE J. ET AL.: "Sam68 RNA Binding Protein Is an In Vivo Substrate for Protein Arginine N-Methyltransferase 1", MOLECULAR BIOLOGY OF THE CELL, vol. 14, 2003, pages 274 - 287, XP003015038 *
KOMATSU Y. ET AL.: "Four different clones of mouse anti-acetyllysine monoclonal antibodies having different recognition properties share a common immunoglobulin framework structure", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 272, 2003, pages 161 - 175, XP004400049 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481690B2 (en) 2008-08-07 2013-07-09 Idexx Laboratories, Inc. Methods for detecting symmetrical dimethylarginine
US9091684B2 (en) 2008-08-07 2015-07-28 Idexx Laboratories, Inc. Methods for detecting symmetrical dimethylarginine
US9970927B2 (en) 2008-08-07 2018-05-15 Idexx Laboratories, Inc. Methods for detecting symmetrical dimethylarginine
CN102628868A (zh) * 2011-12-30 2012-08-08 北京九强生物技术股份有限公司 检测非对称二甲基精氨酸含量的胶乳增强免疫比浊法试剂盒
CN102628868B (zh) * 2011-12-30 2014-09-17 北京九强生物技术股份有限公司 检测非对称二甲基精氨酸含量的胶乳增强免疫比浊法试剂盒
US11035861B2 (en) 2013-09-05 2021-06-15 Idexx Laboratories, Inc. Methods for detecting renal disease
US10775365B2 (en) 2015-02-20 2020-09-15 Idexx Laboratories, Inc. Homogenous immunoassay with compensation for background signal
US11913942B2 (en) 2015-02-20 2024-02-27 Idexx Laboratories, Inc. Homogenous immunoassay with compensation for background signal
CN106290822A (zh) * 2016-07-28 2017-01-04 武汉景川诊断技术股份有限公司 D‑二聚体免疫胶乳微球制备方法及应用
CN106290822B (zh) * 2016-07-28 2018-06-19 武汉景川诊断技术股份有限公司 D-二聚体免疫胶乳微球制备方法及应用
US11422136B2 (en) 2017-10-19 2022-08-23 Idexx Laboratories, Inc. Detection of symmetrical dimethylarginine

Also Published As

Publication number Publication date
JP2007176872A (ja) 2007-07-12

Similar Documents

Publication Publication Date Title
JP3837494B2 (ja) 可溶型ｒａｇｅタンパク質
WO2007074864A1 (fr) Anticorps capable de reconnaitre la dimethylarginine asymetrique, procede pour la production de l&#39;anticorps, et procede pour la detection de proteine ayant un acide amine modifie de maniere post-traductionnelle
EP2754672B1 (fr) Anticorps apte à se lier à une région spécifique de la périostine, et procédé de mesure de la périostine à l&#39;aide de celui-ci
WO2007021255A1 (fr) Anticorps de l’alpha-synucléine
AU600439B2 (en) Ras oncogene peptides and antibodies
JP2003530089A (ja) γ―カルボキシグルタミン酸を提示するエピトープを結合する抗体
US20090221004A1 (en) Caspase-cleavage anti-keratin antibodies for detection of apoptosis
IL210382A (en) An immunoassay for the detection of neurotoxic amino acid associated with neurological disorders
JP4940424B2 (ja) 神経細胞の酸化的損傷のマーカー及びその利用
US20040076992A1 (en) Novel cell adhesion molecule specific to activated leukocyte
US20050100979A1 (en) Methods for detecting oxidative stress
JPH04252954A (ja) タンパクの測定方法、試薬及びキット
KR20150114558A (ko) 인독실 황산의 측정 방법
WO2005037870A1 (fr) Anticorps et utilisation de celui-ci
JP2558956B2 (ja) ヒト・オステオカルシンの免疫学的測定方法、そのための試薬及びキツト、ヒト・オステオカルシンに対する抗体、それを産生するハイブリドーマ及びそれを産生する方法
JP4314365B2 (ja) エンドセリン−２／ｖｉｃに対する特異的な抗体、作製方法、およびその用途
JPH04252955A (ja) 蛋白質の測定方法、試薬及びキット
JPWO2005054296A1 (ja) メチルリジンを認識する抗体及びその製造方法並びにその利用
EP1783142A1 (fr) Acetyllysine capable de reconnaitre un anticorps monoclonal de souris, anticorps etiquête et son utilisation
JP3522877B2 (ja) 抗チロシナーゼモノクローナル抗体Ｆ（ａｂ’）２フラグメント
WO2001042450A1 (fr) Anticorps se liant a l&#39;enzyme du type trypsine des voies aeriennes humaines et son utilisation
JP4726031B2 (ja) Ｘ型ホスホリパーゼａ２の免疫測定方法
JP4635265B2 (ja) エンドセリン−２／ｖｉｃに対する特異的な抗体、作製方法、およびその用途
JP2016114360A (ja) ヒトｔ細胞白血病ウイルスｈｂｚ蛋白質の検出方法
WO2000009739A1 (fr) Anticorps monoclonal agissant contre la trypsine canine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06843427

Country of ref document: EP

Kind code of ref document: A1